Compare WIA & BWAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | WIA | BWAY |
|---|---|---|
| Founded | 2003 | 2003 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 197.8M | 337.9M |
| IPO Year | N/A | 2019 |
| Metric | WIA | BWAY |
|---|---|---|
| Price | $8.25 | $16.97 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $23.50 |
| AVG Volume (30 Days) | 39.2K | ★ 59.5K |
| Earning Date | 01-01-0001 | 11-11-2025 |
| Dividend Yield | ★ 12.29% | N/A |
| EPS Growth | N/A | ★ 213.09 |
| EPS | N/A | ★ 0.13 |
| Revenue | N/A | ★ $49,094,000.00 |
| Revenue This Year | N/A | $330.76 |
| Revenue Next Year | N/A | $22.24 |
| P/E Ratio | ★ N/A | $54.90 |
| Revenue Growth | N/A | ★ 27.08 |
| 52 Week Low | $7.56 | $7.84 |
| 52 Week High | $8.91 | $18.18 |
| Indicator | WIA | BWAY |
|---|---|---|
| Relative Strength Index (RSI) | 39.17 | 54.82 |
| Support Level | $8.24 | $16.75 |
| Resistance Level | $8.29 | $18.18 |
| Average True Range (ATR) | 0.06 | 0.74 |
| MACD | -0.00 | 0.10 |
| Stochastic Oscillator | 25.00 | 69.37 |
Western Asset Inflation Linked Income Fund is a diversified, closed-end management investment company. The primary investment objective of the group is to provide current income while its secondary investment objective is capital appreciation. Under normal market conditions and at the time of purchase, the Fund will invest at least 80% of its total managed assets in inflation-linked securities and at least 60% of its total managed assets in U.S. Treasury Inflation Protected Securities (TIPS). The Fund may also invest up to 40% of its total managed assets in non-U.S. dollar investments.
BrainsWay Ltd is engaged in advanced noninvasive neurostimulation treatments for mental health disorders. The company is advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform technology to improve health and transform lives. Current indications include depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder, and smoking addiction. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. The company derives revenues from the lease and sale of Deep TMS systems.